亚洲精品国产成人一区二区_欧美性xxxxx极品娇小_国产欧美久久一区二区三区_日日麻批免费40分钟无码

China’s First Nectin-4 Targeted ADC Drug 9MW2821 Clinical Progress Released

Release time:Apr 05, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeutic signals in solid tumors, and good safety profile at the recommended phase II dose (RP2D).

Developed with site specific conjugate technology, 9MW2821 is China’s first, global second Nectin-4 targeted ADC approved for clinical study. The multiple ongoing clinical studies include more than 10 different solid tumors, evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The preliminary data show that under RP2D, among 12 UC (Urothelial Carcinoma) patients the ORR (Objective Response Rate) was 50% and DCR (Disease Control Rate) was 100%, and among 6 CC (Cervical Carcinoma) patients, the ORR was 50% and DCR was 100%. Mabwell is promoting the enrollment of multiple cohorts of UC, CC, prostate cancer, HER-2 negative breast cancer, and non-small cell lung cancer. Details will be published in upcoming academic meetings.

Mabwell has also achieved several breakthroughs in new ADC technology platform, optimizing ADC platform by developing IDDC?, a new generation ADC site-specific conjugate technology platform, which is composed of multiple systematized core patented technologies including site-specific conjugate process DARfinity?, special designed linker IDconnect?, novel payload Mtoxin?, and conditional release structure LysOnly?. Developed Based on mentioned systematic patent technologies, the next generation ADCs have better structural homogeneity, quality stability, pharmacodynamics and tolerability, as well as dominant advantage of differentiation.

At present, the advantage of IDDC? platform has been validated in several products under development. Clinical trial application for Trop-2 targeted ADC (R&D code: 9MW2921) has been accepted by NMPA. Clinical trial application for B7-H3 targeted ADC (R&D code: 7MW3711) is expected to be submitted soon. By continuously advancing development of multiple ADC candidates, it is expected that Mabwell will have 3 to 5 ADC products in clinical stage by 2024.

Mabwell has established complete industry chain for ADC, including early discovery, pre-clinical development and pilot scale production. The large-scale commercialized site is expected to be ready for production trial run at Q2, 2023.

主站蜘蛛池模板: 岳西县| 寻乌县| 黑山县| 清水河县| 承德市| 墨玉县| 大悟县| 定陶县| 正阳县| 遵义市| 天峻县| 秀山| 阿荣旗| 垫江县| 密云县| 保亭| 抚州市| 澎湖县| 长葛市| 星子县| 阿拉善右旗| 淮阳县| 镇赉县| 岢岚县| 长宁区| 丹阳市| 西吉县| 鹤壁市| 濮阳市| 历史| 无棣县| 巧家县| 巫山县| 环江| 广元市| 舒兰市| 营口市| 铁力市| 沁源县| 土默特左旗| 通州区|